Flag of the European Union EU Clinical Trials Register Help

Clinical trials for 0

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    31,642 result(s) found for: 0. Displaying page 1,471 of 1,583.
    EudraCT Number: 2012-001597-29 Sponsor Protocol Number: HEM2012ZrOR001 Start Date*: 2012-07-10
    Sponsor Name:VU University Medical Center
    Full Title: Tumor uptake of 89Zirconium-ofatumumab and 89Zirconium-rituximab in diffuse large B cell lymphoma patients
    Medical condition: Diffuse large B cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001963-25 Sponsor Protocol Number: SNOXA12C701 Start Date*: 2022-04-07
    Sponsor Name:NOXXON Pharma AG
    Full Title: An Open-label Phase 2 Study of Olaptesed Pegol (NOX-A12) Combined with Pembrolizumab and Nanoliposomal Irinotecan/5-FU/Leucovorin or Gemcitabine/nab-Paclitaxel inMicrosatellite-Stable Metastatic Pa...
    Medical condition: Pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004958-42 Sponsor Protocol Number: MOM-M281-003 Start Date*: 2019-01-11
    Sponsor Name:Momenta Pharmaceuticals, Inc.
    Full Title: A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease ...
    Medical condition: Early onset Severe Hemolytic Disease of the fetus and newborn (HDFN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10019512 Hemolytic disease due to Rh isoimmunization of fetus or newborn LLT
    Population Age: In utero, Under 18, Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) SE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004860-36 Sponsor Protocol Number: DEXAML-02 Start Date*: 2018-05-15
    Sponsor Name:French Innovative Leukemia Organization (FILO)
    Full Title: A phase II study of dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed AML. A French Innovative Leukemia Organization (FILO) study.
    Medical condition: Elderly patients > 60 years with untreated acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000835 Acute leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003577-34 Sponsor Protocol Number: 2022/702 Start Date*: 2023-01-30
    Sponsor Name:CHU de Besancon
    Full Title: Induction regorafenib in combination with metronomic cyclophosphamide, capecitabine and low-dose aspirin followed by chemotherapy in second line metastatic colorectal cancer. An open-label randomiz...
    Medical condition: cancer colorectal métastatique
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001855-22 Sponsor Protocol Number: M14AFS Start Date*: 2015-01-14
    Sponsor Name:Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital
    Full Title: Phase I/II study with the combination of afatinib and selumetinib in advanced KRAS mutant positive and PIK3CA wildtype non-small cell lung cancer and colorectal cancer
    Medical condition: Patients with histological or cytological proof of advanced KRAS mutant and PIK3CA wildtype non small cell lung cancer (NSCLC) and colorectal cancer (CRC). In part B: for which first-line treatment...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010023 Colorectal neoplasms malignant HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010030 Colorectal cancer recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010034 Colorectal cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010036 Colorectal carcinoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005740-27 Sponsor Protocol Number: 2019/ABM/01/00081 Start Date*: 2021-04-19
    Sponsor Name:Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu
    Full Title: Effect of Intravenous FERRic carboxymaltose on mortality and cardiovascular morbidity, and quality of life in iron deficient patients with recent myocardial infarction
    Medical condition: Recent myocardial infarction associated with iron deficient
    Disease: Version SOC Term Classification Code Term Level
    27.1 10007541 - Cardiac disorders 10028596 Myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005302-26 Sponsor Protocol Number: DW.0701.005.2020P Start Date*: 2023-01-05
    Sponsor Name:John Paul II Hospital
    Full Title: The effect of sacubitril/valsartan versus ramipril on left ventricular function and remodeling in patients with ischemic heart failure with mid-range ejection fraction
    Medical condition: heart failure with moderately reduced ejection fraction (HFmrEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003695-23 Sponsor Protocol Number: 69HCL14-0201 Start Date*: 2015-07-21
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Phase II study evaluating the efficacy of aflibercept for the treatment of inflammatory choroidal neovascularization in young subjects: the ALINEA study
    Medical condition: inflammatory choroidal neovascularization
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002265-36 Sponsor Protocol Number: CHDR1518 Start Date*: 2015-10-22
    Sponsor Name:Centre for Human Drug Research
    Full Title: A randomized, double blind, crossover, placebo controlled class-room experiment to assess the pharmacodynamics and pharmacokinetics of metoprolol in healthy volunteers with different polymorphism o...
    Medical condition: Influence of CYP2D6 polymorphism on metoprolol pharmacokinetics and pharmacodynamics in human volunteers
    Disease: Version SOC Term Classification Code Term Level
    18.0 10007541 - Cardiac disorders 10007521 Cardiac arrhythmias HLGT
    18.0 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000847-62 Sponsor Protocol Number: ATI-450-PsA-201 Start Date*: 2022-10-17
    Sponsor Name:Aclaris Therapeutics, Inc.
    Full Title: A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zunsemetinib vs Placebo in Patients with ...
    Medical condition: Moderate-to-Severe Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-000061-20 Sponsor Protocol Number: 20322 Start Date*: 2019-05-23
    Sponsor Name:Bayer AG
    Full Title: An open-label, multicenter rollover study to provide continued treatment with anetumab ravtansine for participants with solid tumors who were enrolled in previous Bayer-sponsored studies.
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052747 Adenocarcinoma pancreas PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001160 Adenocarcinoma lung LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035605 Pleural mesothelioma malignant advanced LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055108 Thymic cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073064 Epithelioid mesothelioma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017761 Gastric cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051971 Pancreatic adenocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000424-19 Sponsor Protocol Number: 213199 Start Date*: 2020-09-07
    Sponsor Name:Viiv Healthcare UK Limited
    Full Title: A Phase IIIb, open-label, hybrid type III trial evaluating implementation strategies for long-acting cabotegravir plus long-acting rilpivirine every two months in HIV-1 infected, virologically su...
    Medical condition: Human Immunodeficiency Virus Type 1 (HIV-1)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10003582 Asymptomatic human immunodeficiency virus type I infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012644-16 Sponsor Protocol Number: 361/09 Start Date*: 2009-07-24
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: PHASE 2 SINGLE- ARM STUDIES OF TEMOZOLOMIDE IN COMBINATION WITH TOPOTECAN IN REFRACTORY AND RELAPSED NEUROBLASTOMA AND OTHER PAEDIATRIC SOLID TUMOURS
    Medical condition: NEUROBLASTOMA AND OTHER PAEDIATRIC SOLID TUMOURS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029260 PT
    9.1 10039491 PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005569-14 Sponsor Protocol Number: 80202135SLE2001 Start Date*: 2021-08-24
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus
    Medical condition: Active Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) ES (Ongoing) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000586-72 Sponsor Protocol Number: NMSG#25/16 Start Date*: 2017-10-10
    Sponsor Name:Oslo University Hospital
    Full Title: KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) DK (Trial now transitioned) SE (Prematurely Ended) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003039-20 Sponsor Protocol Number: COMAN Start Date*: 2014-11-28
    Sponsor Name:A. O. Istituti Ospitalieri di Cremona
    Full Title: RANDOMIZED PHASE II STUDY WITH SEQUENTIAL NON-CROSS RESISTANT CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED INOPERABLE OR METASTATIC GASTRO-ESOPHAGEAL ADENOCARCINOMA
    Medical condition: Locally advanced inoperable or metastatic gastro-esophageal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030144 Oesophageal adenocarcinoma stage III PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001150 Adenocarcinoma gastric PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030145 Oesophageal adenocarcinoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005743-24 Sponsor Protocol Number: 1214 Start Date*: 2013-07-23
    Sponsor Name:Centre Oscar Lambret
    Full Title: ACTIVITY AND SAFETY OF REGORAFENIB IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA PREVIOUSLY TREATED WITH ANTHRACYCLIN-BASED CHEMOTHERAPY: A MULTINATIONAL, RANDOMIZED, PHASE II, PLACEBO-CONTROLLED...
    Medical condition: Metastatic soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001165-36 Sponsor Protocol Number: FLORENCE_CC-486_HRMDS Start Date*: 2020-10-27
    Sponsor Name:Dipartimento di Medicina Sperimentale e Clinica- Università di Firenze
    Full Title: A Phase 2, Monocentric, Pilot Study to evaluate safety and efficacy of CC 486 (Oral Azacitidine) Plus Best Supportive Care as maintenance of response to sc azacitidine in IPSS higher risk elderly M...
    Medical condition: IPSS and IPSS-R higher Risk ( INT-2 and High risk IPSS; Intermediate, high and very high risk IPSS-R) elderly Myelodysplastic syndrome (MDS) patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004086-38 Sponsor Protocol Number: ARGX-113-2002 Start Date*: 2021-08-06
    Sponsor Name:argenx BV
    Full Title: A Long-Term, Single-Arm, Open-label, Multicenter Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myast...
    Medical condition: Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) BE (Completed) NL (Completed) IT (Completed) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 02 14:47:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA